Gallium maltolate for children with certain brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an oral liquid medicine called gallium maltolate in children with high-grade gliomas or atypical teratoid rhabdoid tumors that have come back or not responded to standard treatment. The goal is to see if it can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 0 to 17 years old.
- You have a type of brain tumor called high-grade glioma, DIPG, or atypical teratoid rhabdoid tumor (ATRT).
- Your tumor has come back or not responded to standard treatment, which includes surgery, radiation, and sometimes chemotherapy.
- You must be able to swallow liquid medicine or have a feeding tube.
- You need to have recovered from side effects of previous treatments.
- You cannot be pregnant or nursing, and if you could become pregnant or father a child, you must agree to use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This trial tests a new way to treat a type of brain tumor called diffuse midline glioma. It uses focused ultrasound to open a tiny gap in the blood-brain barrier, which may help special immune cells (T-cells) reach and attack the tumor. The goal is to see if this combination is safe and helpful.
This trial tests an oral drug called gallium maltolate for people whose glioblastoma (a type of brain cancer) has returned after standard treatment. The drug is given by mouth and may help slow tumor growth.
This trial gives access to gallium maltolate, an oral investigational drug, for people whose glioblastoma has returned and who have no other good options. The goal is to see if it can help control the tumor.
This study tests a combination of three treatments for newly diagnosed high-grade glioma: a drug called ADI-PEG 20, chemotherapy (temozolomide), and radiation therapy. The goal is to see if this combination is safe and effective for children and young adults with this type of brain or spinal cord tumor.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Hear when a new Diffuse Midline Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.